Abstract:Abstract Abstract 1687 Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the t(9;22)(q34;q11) balanced reciprocal translocation within a pluripotent stem cell (SC). The resulting Philadelphia (Ph) chromosome produces BCR-ABL1 fusion gene coding for a deregulated Abl tyrosine-kinase with constitutive and tumorigenic activity. The first line therapy of CML is imatinib mesylate, which targets Bcr-Abl protein, inhibiting proliferation pathways. Complete cytogenetic response can be achieved in 95% of patients treated in the early chronic phase (CP)1. Molecular monitoring of minimal residual disease is crucial to detect poor responses to imatinib and optimizing treatment with second generation tyrosine-kinase inhibitors or allogeneic stem cell transplantation. Residual leukemia is assessed by a quantitative manner evaluating levels of BCR-ABL1 transcripts by real-time reverse transcriptase PCR (qRT-PCR). Although qRT-PCR detects mRNA levels in a very sensitive manner, the negative result is difficult to interpret, because undetectable levels of chimeric transcript can reflect either an effective elimination of leukemia cells, or the presence of a quiescent leukemia SC transcriptionally silent. Methods: We developed a novel highly sensitive method to identify quiescent leukemic cells through quantitative real-time PCR (Q-PCR) targeting the genomic breakpoint sequence1. In CML each patient shows a unique genomic fusion sequence1, that need to be characterized in order to design a specific genomic assay. We selected 14 patients with CML diagnosed in the early CP. We identified junctions sequences by long-range PCR2. We carried out Q-PCR assay using common primer forward and probe in BCR, and 2 different primers reverse, in ABL or BCR, used as control1. The percentage of leukemic cells (LCs) was calculated using the derivation of the δCt formula1: LC= [100*(2/2δCt+1)]/n], where δCt is the difference between amplification cycles of BCR-ABL1 and BCR reactions, and n is the number of experimental replicates. We tested the sensitivity and the efficiency of the method on K562 cell line. According to the human C value, K562 were diluted in normal commercial genomic DNA until 10−4 dilutions. Eight CML patients in early CP were the object of this study. A patient specific Q-PCR assay was performed on DNA obtained at diagnosis and subsequently applied to monitor minimal residual disease during Imatinib treatment for up to 8 years, for a total of 61 samples. In parallel the same peripheral blood samples were tested by standard qRT-PCR, and the percentage of residual disease (international scale) measured by mRNA was compared with DNA analysis. Results: Positive levels of mRNA were obtained in 79% of samples analyzed by qRT-PCR,while we detected Ph-positive cells in 92% of samples. In all positive samples for chimeric transcript we measured positive levels of corresponding genomic DNA, confirming the sensitivity of the Q-PCR method. In 13% of samples, with undetectable levels of mRNA, we observed the persistence of quiescent leukemic cells, transcriptionally silent like shown by patient 2 in figure 1. This could probably indicate the presence of pluripotent LSCs or progenitor cells, that does not respond to imatinib treatment. Finally undetectable levels of mRNA were confirmed by a correspondent DNA negativity in 8,2% of the samples. This datum should be investigated further in order to establish if the disease was been eradicated. Patients negative by mRNA detection in several consecutive follow-ups could be candidates to stop imatinib therapy. The development of a DNA base technique could be a powerful tool to evaluate the effective presence/absence of leukemic cells. Patient 8 resulted negative at 70 months monitored by RNA and DNA technique could be a candidate to stop the therapy (figure 2). Conclusion: Although the initial characterization of genomic breakpoint sequence is still time consuming, it may provide a patient-specific DNA biomarker that can be used to detect the presence of quiescent leukemic cells otherwise undetectable using a conventional qRT-PCR. The DNA genomic Q-PCR could be a very sensitive and direct technique to detect minimal residual disease in CML patients treated with tyrosine-kinase inhibitors and allogeneic transplantation. We thank AIL Varese and Bergamo. Disclosures: No relevant conflicts of interest to declare.

Different Kinetic Patterns of BCR‐ABL Transcript Levels in Imatinib‐treated Chronic Myeloid Leukemia Patients after Achieving Complete Cytogenetic Response

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Outcome Prediction by the Transcript Level of BCR-ABL at 3 Months in Patients with Chronic Myeloid Leukemia Treated with Imatinib--a Single Institution Historical Experience.

Molecular Responses of Late Chronic Phase Chronic Myeloid Leukemia Patients after Achieving Complete Cytogenetic Responses with Imatinib Treatment: a 6-Year Follow-Up

[Monitoring Bcr/abl Mrna Levels in Imatinib Mesylate Treated Chronic Myeloid Leukemia Patients by Real-Time Quantitative RT-PCR].

Which Method Better Evaluates the Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib Treatment, BCR-ABL(IS) or Log Reduction from the Baseline Level?

Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia

THE DIFFERENCES AND CORRELATIONS OF BCR-ABL TRANSCRIPTS BETWEEN PERIPHERAL BLOOD AND BONE MARROW ASSAYS ARE ASSOCIATED WITH THE MOLECULAR RESPONSES IN THE BONE MARROW FOR CHRONIC MYELOGENOUS LEUKEMIA

[Monitoring Bcr-Abl Mrna Levels by Real-Time Quantitative RT-PCR in Chronic Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation].

Predictive Value of Molecular Response after Treatment with Tyrosine Kinase Inhibitor for 3 Months in Patients with Chronic Myeloid Leukemia

[Comparison of Simultaneous Bone Marrow Cytogenetic and Peripheral Blood Molecular Responses in Chronic Myeloid Leukemia].

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years

Real-time Reverse-Transcriptase Polymerase Chain Reaction in Monitoring BCR/ABL Transcript Levels in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cells Transplantation

Investigation of Long-Term Follow-Up Results of 135 Patients with Chronic Myeloid Leukemia Receiving Imatinib

Treatment-Free Remission Era: BCR-ABL1 Mrna Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

The Significance of Serial Monitoring of Bcr-Abl Transcripts Levels after Allogeneic Hematopoietic Stem Cell Transplantation in Screening Chronic Myeloid Leukemia Patients with Low Relapse

Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.

Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia